Beneficial Ownership Report · SCHEDULE 13G
Beta Bionics, Inc.
BBNXNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- BETA BIONICS INC
- Company CIK
- 0001674632
- Street
- 11 HUGHES
- City
- IRVINE
- State / country code
- CA
- Postal code
- 92618
Statement details
- Security class
- COMMON STOCK
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- T. Rowe Price Associates, Inc.
- Citizenship / organization
- MD
- Reporting person type
- IA
- Aggregate amount owned
- 8,943,061
- Percent of class
- 16.6
- Sole voting power
- 8,939,271
- Shared voting power
- 0
- Sole dispositive power
- 8,943,061
- Shared dispositive power
- 0
- Aggregate excludes certain shares
- N
Item 1
Issuer
BETA BIONICS INC
Principal executive office address
11 HUGHES, IRVINE, CA, 92618
Item 2
Citizenship
Maryland
Filing person
T. Rowe Price Associates, Inc.
Principal business or residence address
1307 Point Street, Baltimore, MD 21231
Item 3
Not applicable indication
N
Type of filing person
IA
Item 4
Percent of class
16.6
Amount beneficially owned
8943061
Sole voting power
8939271
Shared voting power
0
Sole dispositive power
8943061
Shared dispositive power
0
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) [T. ROWE PRICE HEALTH SCIENCES FUND ]: T. ROWE PRICE HEALTH SCIENCES FUND, of which T. Rowe Price Associates, Inc. is the investment adviser, holds the securities reported herein in their investment portfolio managed by T. Rowe Price Associates, Inc. and such funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that they hold. T. ROWE PRICE HEALTH SCIENCES FUND has an interest in 2,408,699 of the class reported herein representing 5.4% of the class.
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
Signature 1
- Reporting person
- T. Rowe Price Associates, Inc.
- Signed
- Ellen York
- Title
- Vice President
- Date
- 10/07/2026
Company context
We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Diabetes is a serious, chronic and often lifelong condition with no known cure that is characterized by extended periods of elevated levels of glucose in the bloodstream, or hyperglycemia, resulting from the body’s inability to either produce or effectively utilize the hormone insulin. To treat their diabetes, PWD must undergo a rigorous regimen of daily insulin substitution, as elevated levels of glucose in the blood over time can lead to serious and often life-threatening cardiovascular, metabolic and nervous system complications. Despite decades of innovation that have advanced the quality of care available, a significant unmet need remains as the vast majority of PWD still cannot manage their diabetes effectively. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. We believe this marks a significant advancement over other insulin delivery technologies by offering a differentiated combination of improved glycemic control an